Biotechnology
MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease
FOSTER CITY, Calif., Jan. 29, 2026 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant bacterial infections, recently announced that the U.S. Food and Drug Administration (FDA) ...
XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision
* Global thought leaders presented cutting-edge research at the 2026 International Symposium on Molecular Glue Drug Discovery. * XtalPi unveils the AI-driven XGlue™ platform to enable rapid, closed-loop molecular glue drug discovery. * Cross-sector discussions emphasized the need for bridgin...
WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific ...
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- QureBio Ltd., a clinical-stage biotech company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today revealed in 2026 ASCO abstract submission a...
Nona Biosciences Co-founds Innovative Alliance for Translational Medicine in Immunological Diseases, Advancing a New IIT-Driven Ecosystem
CAMBRIDGE, Mass., Jan. 28, 2026 /PRNewswire/ -- Recently, as a core co-founder and co-organizer, Nona Biosciences participated in the launch of the "Innovative Alliance for Translational Medicine in Immunological Diseases" (the "Alliance") and attended its inauguration ceremony. The Alliance brin...
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
* Ranked in the top one percent among more than 150,000 companies assessed globally * Recognized for strengthened sustainability management across all four assessment categories INCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract developm...
Asthma and Allergy Drug Development Is Failing Too Often--A Translational Reset Is Needed: HKEY-AIRx™1.0
BOSTON and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, today announced a translational preclinical strategy,HKEY-AIRxTM1.0 designed to address one of the most persistent problems facing biotech leadership: w...
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center...
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC)....
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
* Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. * License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset. *...
Libevitug Approved in China as First-in-Class Treatment for Hepatitis D
BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis. Libevitug...
Moyom Biotechnology Announces Strategic Partnership with WPP Group to Elevate Aphranel's "Poetics of Time" Brand Positioning
SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- Moyom Biotechnology today announced a strategic partnership with WPP Group, a leading creative transformation company that provides integrated brand, media, public relations, data, and technology solutions worldwide. Headquartered in London, WPP Group oper...
BIOSeedin Winter Innovation Partnering Summit:J.P.Morgan Spotlight
SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- To enable Chinese innovative pharmaceutical companies to more efficiently connect with international resources, bioSeedin, a platform facilitating cooperation in innovative drug assets, hosted the BIOSeedin Winter Innovation Partnering Summit inSan Fra...
Jin Medical International Ltd. To Host Management Fireside Chat
CHANGZHOU, China, Jan. 26, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment inChina, announced today that its Chief Executive Officer, tog...
Divamics Showcases Lead Autoimmune Program DVI-001 and Unveils New Metabolic Program DVI-004 at JPM Week 2026
SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- Divamics (DIVAMICS), an AI-driven biotechnology company specializing in high-precision molecular discovery, highlighted the significant advancement of its internal pipeline during the Biotech Showcase™ at JPM Week 2026. The company provided updated mil...
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline
SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Developm...
Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor
* Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study inthe United States. The Phase I clinical trial aims to evaluate safety, tolerability, and pharmacokinetics profiles. * ISM8969 is a novel oral therapeutic candi...
Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.
AUCKLAND, New Zealand, Jan. 21, 2026 /PRNewswire/ -- Aroa Biosurgery Limited is pleased to announce that the latest publication from its ongoing prospective study, theMyriad Augmented Soft Tissue Reconstruction Registry (MASTRR), has been published in theJournal of Trauma and Injury. MASTRR is t...
Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.
SHANGHAI, Jan. 22, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed ina clinical trial in the U.S. of its independently developed novel CDH17-targeting antibody-drug co...
SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding
* CEPI to provide up to USD 30 million to support development of MSD's Zaire ebolavirus vaccine * Collaboration addresses manufacturing complexity and cold-chain challenges to improve yield and thermostability * Partnership aims to expand affordable and sustainable vaccine access in low- an...
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 319 media titles]
2026-01-23 11:03Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 307 media titles]
2026-01-23 09:00Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 298 media titles]
2026-01-22 15:16Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00